EuroPCR 2023: Late-Breaking Science Video Collection
Published: 18 May 2023
-
Views:
2136 -
Likes:
7
-
Views:
2136 -
Likes:
7
-
Up Next
-
2m 35sPart 1 | Session 7 FAME III Three-Year Follow-Up
-
29m 21sPart 2 | Session 1 View from the Thoraxcenter: EuroPCR 23 Late-breaking Science Preview
-
30m 41sPart 2 | Session 2 View from the Thoraxcenter: What's Hot at EuroPCR 23?
-
1m 5sPart 4 | Session 1 Dr Lim: Patient Care and Finding Your Passion
-
1m 51s
-
1m 45sPart 4 | Session 3 Dr Sorajja: Why He Chose Cardiovascular Medicine
-
5m 41sPart 1 | Session 1 EBC TWO Five Year Follow-Up: Two-Stent Vs One for Large Bifurcation Lesions Sandeep Arunothayaraj
-
6m 12sPart 1 | Session 2 BASILICA Vs Chimney-Stenting for TAVR-Related Coronary Obstruction Antonio Mangieri
-
3m 15sPart 1 | Session 3 DRAGONFLY-DMR: Safety and Effectiveness of Dragonfly TMVR System for Mitral Regurgitation D Scott Lim
-
3m 30sPart 1 | Session 4 TRILUMINATE Pivotal: TEER for Tricuspid Regurgitation Paul Sorajja
-
6m 7sPart 1 | Session 5 EBC MAIN Three-Year Follow Up David Hildick-Smith
Overview
Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
Hear commentary on the practice-changing trials of EuroPCR 2023 from selected faculty in our Highlights Reviews.
Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of EuroPCR 2023.
More from this programme
Part 1
Expert Interviews
Short, concise overviews of the key data revealed at EuroPCR 2023, focussing on the results and impact on future research.
Part 2
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at EuroPCR 2023.
Part 3
Highlights Reviews
Commentary on the top late-breaking trials of EuroPCR 2023, as chosen by selected faculty.
Part 4
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
About the episode
EuroPCR 23 —We are joined by Dr Abhijeet Dhoble (UT Health, US) to discuss the findings of the TVT-registry analysis on transcatheter aortic valve replacement (TAVR) in patients with cardiogenic shock. (NCT01737528)
The analysis aims to evaluate the outcomes of balloon-expandable bioprosthetic transcatheter aortic valve replacement (TAVR) with SAPIEN 3 and SAPIEN 3 Ultra bioprosthesis in patients with cardiogenic shock. The findings demonstrate that TAVR is a safe and effective treatment option, with acceptable outcomes observed at both 30 days and 1-year post-procedure.
Interview Questions:
- What is the background of the analysis? What do we know about contemporary TAVR in cardiogenic shock patients?
- How did you define cardiogenic shock?
- What is study design and patient cohort?
- What is data presented at EuroPCR? What conclusions can be made?
- Are there any predictors or risk factors that can help identify patients who would benefit the most from TAVI in cardiogenic shock?
- Were are the knowledge gaps, and how can this be aided with further research?
Recorded on-site at EuroPCR 2023, Paris.
Comments